Effectiveness and Adherence of Golimumab in Rheumatoid Arthritis

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

200 participants

Study Classification

OBSERVATIONAL

Study Start Date

2019-07-01

Study Completion Date

2021-03-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This will be a prospective, observational, single-arm, registry study based on data received from Chinese Registry of rheumatoid arthritis (CREDIT) database to register 200 Chinese RA patients treated with golimumab in one year. Patient characteristic, clinical effectiveness and drug adherence of golimumab will be evaluated.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Study of Subcutaneous Golimumab in Chinese Patients With Active Rheumatoid Arthritis Despite Methotrexate Therapy

NCT01248780

Rheumatoid Arthritis

COMPLETED PHASE3

Golimumab for Adherence in Rheumatoid Arthritis

NCT03729349

Arthritis, Rheumatoid

COMPLETED

Study of the Safety and Efficacy of Golimumab in Chinese Patients With Ankylosing Spondylitis

NCT01248793

Ankylosing Spondylitis

COMPLETED PHASE3

A Safety and Efficacy Study of Golimumab (CNTO148) in Patients With Active Rheumatoid Arthritis (RA)

NCT00771251

Rheumatoid Arthritis

COMPLETED PHASE3

An Effectiveness and Safety Study of Intravenous Golimumab in Patients With Active Rheumatoid Arthritis Despite Treatment With Methotrexate Therapy

NCT00973479

Arthritis, Rheumatoid

COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This multicenter (12 centers), prospective program will register 200 RA patients routinely receiving golimumab treatment. Doctor will record the disease evaluation, concomitant drug, adverse events and laboratory tests based on patient's visit till they withdraw from clinical visit. Doctor will still collect above information whether patient interrupt or stop golimumab till the end of program or patient withdraw permanently.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Arthritis, Rheumatoid

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

RA patients

Patients (or a representative) must provide informed consent before any procedures occur.

1. Main Inclusion Criteria:

* 18 years and older
* Fulfil the ACR/EULAR classification criteria for RA in 2010
* Patients able to understand and complete self-evaluation questionnaires.
2. General Exclusion Criteria:

* Contraindications for golimumab
* Prior exposure to TNFi/JAKi

Golimumab

Intervention Type DRUG

This multicenter (12 centers), prospective program will register 200 RA patients routinely receiving golimumab treatment. Doctor will record the disease evaluation, concomitant drug, adverse events and laboratory tests based on patient's visit till they withdraw from clinical visit. Doctor will still collect above information whether patient interrupt or stop golimumab till the end of program or patient withdraw permanently.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Golimumab

This multicenter (12 centers), prospective program will register 200 RA patients routinely receiving golimumab treatment. Doctor will record the disease evaluation, concomitant drug, adverse events and laboratory tests based on patient's visit till they withdraw from clinical visit. Doctor will still collect above information whether patient interrupt or stop golimumab till the end of program or patient withdraw permanently.

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* \- 18 years and older
* Fulfil the ACR/EULAR classification criteria for RA in 2010
* Patients able to understand and complete self-evaluation questionnaires.